Cilostazol - reversibly oppresses aggregation of thrombocytes caused by various incentives, surpassing in this respect Аspirin, Dipiridamolum, Тiclopidine and Pentoxifylline. It also inhibits formation of arterial blood clots and proliferation of smooth muscle cells, possesses vasodilating action.
Your order will be packed safe and secure and dispatched within 24 hours. This is exactly how your parcel will look like (pictures of a real shipping item). It has a size and a look of a regular private letter (9.4x4.3x0.3 inches or 24x11x0.7cm) and it does not disclose its contents
Cilostazol product description
Cilostazol is an antiplatelet drug that increases intracellular cAMP content in platelets, selectively inhibits type 3 phosphodiesterase, thereby lessens the platelet aggregate ability. According to experimental data, cilostazol suppresses the synthesis of DNA and inhibits the growth of smooth muscle cells, in addition, it has a vasodilating action. These properties of cilostazol allowed us to advise it for the prevention of restenosis after implantation of metallic uncoated stents. Cilostazol is consumed to eliminate the functional limitations of the limbs that arise from cramping pains with the insufficient circulation. So, in case of the Charcot syndrome, this medical remedy allows patients to walk much longer without feeling much discomfort.
Cilostazol safety information
This pharmaceutical product should be taken on an empty stomach, at least 30 minutes before or two hours after a meal. The maximum effect of the remedy may appear only after 12 weeks of its proper reception, although often the signs of the successful healing with the medicine are palpable earlier. Immediately stop taking this medical remedy if bleeding occurs from the eyes. Also, you should seek an advice if you have got bruises during the therapy. If the patient needs to undergo surgery, then the drug should be withdrawn 5 days before the surgery. If it is administered in parallel with the other chemicals, which are thinning the blood or lowering blood pressure, as well as with inhibitors or inducers of CYP 3A4, CYP 2C19 or CYP 3A4 substrates, it is necessary to exercise extra caution. If during therapy, the patient has a sore throat or hyperthermia, a laboratory test should be carried out for pathological changes. In case of such changes, the medical care with Cilostazol should be discontinued immediately.
If the patient underwent a surgery on coronary vessels in the last half of the year, then Cilostazol should be assigned.
Cilostazol is not received if the patient has detected to have any of the following condition: hypersensitivity to the basic substance or to any component of this pharmaceutical product, any known tendency to bleeding (eg, gastric or duodenal ulcer in the acute stage, recent hemorrhagic stroke), congestive heart failure, moderate or severe hepatic insufficiency , severe renal failure.
The very medical preparation is not prescribed for the therapy of pregnant women and children since there are no data on studies of possible negative consequences.
Cilostazol side effects
From the side of the nervous system: a headache, dizziness.
From the side of the cardiovascular system: palpitation, tachycardia, angina pectoris, arrhythmia, ventricular extrasystoles.
On the part of the respiratory tract: rhinitis, pharyngitis.
On the part of the gastrointestinal tract: diarrhea, nausea, vomiting, dyspepsia, flatulence, abdominal pain, impaired excrement.
On the part of the skin: rash, itching.
Common disorders: chest pain, bruises, asthenia.